Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening.

Steele RJ, Kostourou I, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA, Fraser C.

BMJ. 2010 Oct 27;341:c5531. doi: 10.1136/bmj.c5531.

2.

Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.

Steele RJ, McClements PL, Libby G, Carey FA, Fraser CG.

Colorectal Dis. 2014 Jan;16(1):28-32. doi: 10.1111/codi.12393.

PMID:
24034143
3.

Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.

Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C.

Gut. 2015 Feb;64(2):282-91. doi: 10.1136/gutjnl-2013-306144. Epub 2014 May 7.

4.

Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.

Tam TK, Ng KK, Lau CM, Lai TC, Lai WY, Tsang LC.

Hong Kong Med J. 2011 Oct;17(5):350-7.

5.

Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.

McNamara D, Leen R, Seng-Lee C, Shearer N, Crotty P, Neary P, Walsh P, Boran G, O'Morain C.

Eur J Gastroenterol Hepatol. 2014 Dec;26(12):1415-21. doi: 10.1097/MEG.0000000000000207.

PMID:
25244415
6.

Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer.

Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, Mowat NA, Wilson JA, Kenicer M, Carey FA, Fraser CG.

Gut. 2009 Apr;58(4):530-5. doi: 10.1136/gut.2008.162883. Epub 2008 Nov 26.

PMID:
19036949
7.

Negative screening colonoscopy after a positive guaiac faecal occult blood test: not a contraindication to continued screening.

Carrera A, McClements PL, Watling C, Libby G, Weller D, Brewster DH, Carey FA, Fraser CG, Steele RJ.

Colorectal Dis. 2012 Aug;14(8):943-6. doi: 10.1111/j.1463-1318.2011.02849.x.

PMID:
21981347
8.

Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain).

Peris M, Espinàs JA, Muñoz L, Navarro M, Binefa G, Borràs JM; Catalan Colorectal Cancer Screening Pilot Programme Group.

J Med Screen. 2007;14(2):81-6.

PMID:
17626707
9.

Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.

UK Colorectal Cancer Screening Pilot Group.

BMJ. 2004 Jul 17;329(7458):133. Epub 2004 Jul 5.

10.

Performance measures in three rounds of the English bowel cancer screening pilot.

Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, Ramsell P, Patnick J, Weller DP.

Gut. 2012 Jan;61(1):101-7. doi: 10.1136/gut.2010.236430. Epub 2011 May 10.

12.

Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.

Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E.

Gastroenterology. 2012 Mar;142(3):497-504. doi: 10.1053/j.gastro.2011.11.024. Epub 2011 Nov 19.

PMID:
22108194
13.

Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women.

Blanks RG, Benson VS, Alison R, Brown A, Reeves GK, Beral V, Patnick J, Green J.

Br J Cancer. 2015 Apr 28;112(9):1562-7. doi: 10.1038/bjc.2015.69. Epub 2015 Mar 5.

14.

Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.

Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E, Elferink MA, Fockens P, Stroobants AK, Bossuyt PM, Dekker E.

Cancer Epidemiol. 2015 Jun;39(3):388-93. doi: 10.1016/j.canep.2015.03.012. Epub 2015 Apr 21.

PMID:
25910865
15.

Population colorectal cancer screening with fecal occult blood test.

Rennert G, Rennert HS, Miron E, Peterburg Y.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1165-8.

16.

Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.

Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG.

J Natl Cancer Inst. 1993 Aug 18;85(16):1311-8.

PMID:
8340943
17.

Screening for colorectal cancer in Italy: 2005 survey.

Zorzi M, Barca A, Falcini F, Grazzini G, Pizzuti R, Ravaioli A, Sassoli de Bianchi P, Senore C, Sigillito A, Vettorazzi M, Visioli C.

Epidemiol Prev. 2007 Mar-Jun;31(2-3 Suppl 2):49-60.

18.

Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.

Grazzini G, Ciatto S, Cislaghi C, Castiglione G, Falcone M, Mantellini P, Zappa M; Working Group of Regional Reference Centre for Oncological Screening of Tuscany.

J Med Screen. 2008;15(4):175-81. doi: 10.1258/jms.2008.008032.

PMID:
19106257
19.

Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.

Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD.

Gut. 2012 Jul;61(7):1036-40. doi: 10.1136/gutjnl-2011-300774. Epub 2011 Nov 3.

PMID:
22052062
20.

The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.

Manfredi S, Philip J, Campillo B, Piette C, Durand G, Riou F, Bretagne JF.

Eur J Cancer Prev. 2011 Jul;20(4):277-82. doi: 10.1097/CEJ.0b013e3283457290.

PMID:
21633201

Supplemental Content

Support Center